EP4387998A4 - Anticorps et fragments de liaison à l'antigène dirigés contre cd155 et leurs méthodes d'utilisation - Google Patents

Anticorps et fragments de liaison à l'antigène dirigés contre cd155 et leurs méthodes d'utilisation

Info

Publication number
EP4387998A4
EP4387998A4 EP21954398.0A EP21954398A EP4387998A4 EP 4387998 A4 EP4387998 A4 EP 4387998A4 EP 21954398 A EP21954398 A EP 21954398A EP 4387998 A4 EP4387998 A4 EP 4387998A4
Authority
EP
European Patent Office
Prior art keywords
antigen
antibodies
binding fragments
fragments against
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21954398.0A
Other languages
German (de)
English (en)
Other versions
EP4387998A1 (fr
Inventor
Aftab S Karim
Robert Holgate
Arron Hearn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tasrif Pharmaceutical LLC
Original Assignee
Tasrif Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tasrif Pharmaceutical LLC filed Critical Tasrif Pharmaceutical LLC
Publication of EP4387998A1 publication Critical patent/EP4387998A1/fr
Publication of EP4387998A4 publication Critical patent/EP4387998A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21954398.0A 2021-08-20 2021-08-20 Anticorps et fragments de liaison à l'antigène dirigés contre cd155 et leurs méthodes d'utilisation Pending EP4387998A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/046855 WO2023022729A1 (fr) 2021-08-20 2021-08-20 Anticorps et fragments de liaison à l'antigène dirigés contre cd155 et leurs méthodes d'utilisation

Publications (2)

Publication Number Publication Date
EP4387998A1 EP4387998A1 (fr) 2024-06-26
EP4387998A4 true EP4387998A4 (fr) 2026-01-28

Family

ID=85239697

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21954398.0A Pending EP4387998A4 (fr) 2021-08-20 2021-08-20 Anticorps et fragments de liaison à l'antigène dirigés contre cd155 et leurs méthodes d'utilisation

Country Status (6)

Country Link
EP (1) EP4387998A4 (fr)
JP (1) JP2024531426A (fr)
CN (1) CN118302445A (fr)
AU (1) AU2021460932A1 (fr)
CA (1) CA3229327A1 (fr)
WO (1) WO2023022729A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025092966A1 (fr) * 2023-11-02 2025-05-08 重庆精准生物技术有限公司 Fragment peptidique tigit spécifique
CN119431583B (zh) * 2024-12-19 2025-09-30 重庆国际免疫创新中心有限公司 靶向cd155的抗体或抗原结合片段及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074324A2 (fr) * 2003-02-24 2004-09-02 Xerion Pharmaceuticals Ag Modulation de la fonction du recepteur du poliovirus
WO2021070181A1 (fr) * 2019-10-08 2021-04-15 Nectin Therapeutics Ltd. Anticorps dirigés contre le récepteur du poliovirus (pvr) et leurs utilisations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518033B1 (en) * 1998-08-05 2003-02-11 The Research Foundation Of State University Of New York Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment
US20100291071A1 (en) * 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
US9926377B2 (en) * 2014-05-22 2018-03-27 Genentech, Inc. Anti-GPC3 antibodies and immunoconjugates
JP6822849B2 (ja) * 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
JP5995117B2 (ja) * 2015-01-26 2016-09-21 国立大学法人 筑波大学 可溶型ｃｄ１５５タンパク質を用いた癌の検出方法
WO2017046746A1 (fr) * 2015-09-15 2017-03-23 Acerta Pharma B.V. Associations thérapeuthiques d'un inhibiteur de la btk et d'une molécule de liaison à gitr, d'un agoniste de 4-1bb, ou d'un agoniste d'ox40
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
CA3015619A1 (fr) * 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anticorps specifiques du recepteur du poliovirus humain (pvr)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074324A2 (fr) * 2003-02-24 2004-09-02 Xerion Pharmaceuticals Ag Modulation de la fonction du recepteur du poliovirus
WO2021070181A1 (fr) * 2019-10-08 2021-04-15 Nectin Therapeutics Ltd. Anticorps dirigés contre le récepteur du poliovirus (pvr) et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOBIS P. ET AL: "Production of a Monoclonal Antibody against an Epitope on HeLa Cells that Is the Functional Poliovirus Binding Site", JOURNAL OF GENERAL VIROLOGY, vol. 66, no. 12, 1 December 1985 (1985-12-01), pages 2563 - 2569, XP093267104, ISSN: 0022-1317, DOI: 10.1099/0022-1317-66-12-2563 *
See also references of WO2023022729A1 *

Also Published As

Publication number Publication date
CN118302445A (zh) 2024-07-05
AU2021460932A1 (en) 2024-03-07
EP4387998A1 (fr) 2024-06-26
JP2024531426A (ja) 2024-08-29
CA3229327A1 (fr) 2023-02-23
WO2023022729A1 (fr) 2023-02-23

Similar Documents

Publication Publication Date Title
EP4225373A4 (fr) Anticorps anti-dectine-1 et leurs méthodes d'utilisation
EP3755690A4 (fr) Inhibiteurs d'egfr et leurs procédés d'utilisation
EP4090685A4 (fr) Anticorps anti-gal3 et méthodes d'utilisation
EP4007605A4 (fr) Anticorps anti-fcrn et leurs procédés d'utilisation
EP4291578A4 (fr) Anticorps anti-cd3 et procédés d'utilisation associés
EP4021498A4 (fr) Anticorps anti-tgf-bêta 1 latent inter-espèces et leurs procédés d'utilisation
EP4240417A4 (fr) Anticorps anti-fcrn et leurs méthodes d'utilisation
EP4061848A4 (fr) Anticorps anti-ror-2 et méthodes d'utilisation
EP4401764A4 (fr) Anticorps anti-siglec-6 et leurs méthodes d'utilisation
EP4072436A4 (fr) Appareil d'agrafage et procédés d'utilisation
EP4522583A4 (fr) Inhibiteurs de pi3k alpha et leurs procédés d'utilisation
EP3574010A4 (fr) Anticorps anti-sclérostine et procédés d'utilisation
EP4466293A4 (fr) Complexe de protéine ciblant cd47/pd-l1 et ses procédés d'utilisation
EP4031188A4 (fr) Radiomarquage d'immunoglobuline anti cd-45 et ses méthodes d'utilisation
EP4412617A4 (fr) Nouveaux inhibiteurs de la pikfyve et leurs méthodes d'utilisation
EP4499697A4 (fr) Anticorps anti-récepteur alpha du folate et procédés d'utilisation
EP4399230A4 (fr) Récepteur antigénique chimérique anti-gpc3 et ses procédés d'utilisation
EP4387998A4 (fr) Anticorps et fragments de liaison à l'antigène dirigés contre cd155 et leurs méthodes d'utilisation
EP3755697A4 (fr) Agents de dégradation d'egfr et procédés d'utilisation de ceux-ci
EP4069085A4 (fr) Appareil d'imagerie protégé et son procédé d'utilisation
EP4041740A4 (fr) Polymères de benzoxaborole et méthodes d'utilisation
EP4333893A4 (fr) Anticorps anti-tigit, anticorps anti-cd96 et leurs procédés d'utilisation
EP4392448A4 (fr) Anticorps pilra et méthodes d'utilisation de ceux-ci
EP4412661A4 (fr) Polythérapies à base d'anticorps anti-trop2 et leurs méthodes d'utilisation
EP4341299A4 (fr) Anticorps anti-cea et méthodes d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20250813BHEP

Ipc: C07K 16/08 20060101ALI20250813BHEP

Ipc: A61K 39/42 20060101ALI20250813BHEP

Ipc: A61P 35/00 20060101ALI20250813BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20260107

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20251222BHEP

Ipc: C07K 16/08 20060101ALI20251222BHEP

Ipc: A61K 39/42 20060101ALI20251222BHEP

Ipc: A61P 35/00 20060101ALI20251222BHEP